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Objectives This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopi-
dogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics.
Background Platelet inhibition by clopidogrel is highly variable. Patients with reduced inhibition have increased risk for major
adverse cardiovascular events. Identification of factors contributing to clopidogrel’s variable response is needed
to improve platelet inhibition and reduce risk for cardiovascular events.
Methods Healthy subjects (n  160; ages 20 to 53 years; homozygous CYP2C19 extensive metabolizer genotype; no nico-
tine for 6 weeks, prescription drugs for 4 weeks, over-the-counter drugs for 2 weeks, and no caffeine or alcohol
for 72 h; confined; restricted diet) received clopidogrel 75 mg/day for 9 days, at which time clopidogrel pharma-
cokinetic and pharmacodynamic endpoints were measured.
Results At steady-state, clopidogrel active metabolite (clopidogrelAM) pharmacokinetics varied widely between subjects
(coefficients of variation [CVs] 33.8% and 40.2% for clopidogrelAM area under the time-concentration curve and
peak plasma concentration, respectively). On-treatment vasodilator stimulated phosphoprotein P2Y12 platelet
reactivity index (PRI), maximal platelet aggregation (MPA) to adenosine phosphate, and VerifyNow P2Y12 plate-
let response units (PRU) also varied widely (CVs 32% to 53%). All identified factors together accounted for only
18% of intersubject variation in pharmacokinetic parameters and 32% to 64% of intersubject variation in PRI,
MPA, and PRU. High on-treatment platelet reactivity was present in 45% of subjects.
Conclusions: Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite rigorous exclusion or control of known
disease, polymorphisms (CYP2C19, CYP3A5, ABCB1, PON1), noncompliance, co-medications, diet, smoking, al-
cohol, demographics, and pre-treatment platelet hyperreactivity. Thus, as yet unidentified factors contribute to
high on-treatment platelet reactivity with its known increased risk of major adverse cardiovascular events. (A
Study of the Effects of Multiple Doses of Dexiansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the
Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants: NCT00942175) (J Am Coll
Cardiol 2013;61:872–9) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.040investigator). Drs. Frelinger and Michelson have received research grants from
GLSynthesis and Lilly. Dr. Michelson has been a member of the Data Monitoring
Committee of a clinical trial sponsored by Lilly. Dr. Bhatt is a member of the
Advisory Board for Medscape Cardiology; a member of the Board of Directors for the
Boston VA Research Institute and the Society of Chest Pain Centers; and is the ChairFrom the *Center for Platelet Research Studies, Division of Hematology/Oncology,
Boston Children’s Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts;
†Harvard Medical School, Boston, Massachusetts; ‡VA Boston Healthcare System,
Brigham and Women’s Hospital, Boston, Massachusetts; and the §Takeda Global
Research & Development Center, Inc., Deerfield, Illinois. This study was supported
in part by a research grant from Takeda Global Research & Development Center,
Inc., Deerfield, Illinois to Children’s Hospital Boston (Alan D. Michelson, principal
of the American Heart Association Get With The Guidelines Science Subcommittee;
he has received honoraria from the American College of Cardiology (Editor, Clinical
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February 26, 2013:872–9 Clopidogrel Response VariabilityAntiplatelet therapy with clopidogrel reduces coronary
events in patients with acute coronary syndrome (1). How-
ever, platelet inhibition by clopidogrel is highly variable, and
patients with reduced platelet inhibition have an increased
risk for major adverse cardiovascular events (2). Esterases
degrade 85% of absorbed clopidogrel, leaving only 15% to
e converted by the cytochrome P-450 family of enzymes
3,4) and possibly paraoxonase 1 (PON1) (5), to the active
etabolite required for inhibition of the platelet adenosine
iphosphate (ADP) receptor, P2Y12. Variability in clopi-
dogrel pharmacokinetics and pharmacodynamics has been
attributed to absorption (e.g., diet or polymorphisms in the
transporter molecule ABCB1 [6–8]), smoking (which alters
ytochrome P-450 levels) (9,10), polymorphisms in
YP2C19 (8) and/or PON1 (5), drug–drug interactions
e.g., proton pump inhibitors [PPIs] [11,12] statins), and
ntrinsic variation in platelet function before exposure to
lopidogrel (13–15). However, it remains unclear whether
hese factors fully explain the variability observed in clopi-
ogrel pharmacokinetics and pharmacodynamics, or if a
ignificant portion of the variability is due to still unknown
actors. Here, we report the variability in clopidogrel phar-
acokinetics and pharmacodynamics when known factors
re rigorously excluded or controlled.
ethods
tudy design. We performed a randomized, 2-period,
rossover design study to assess the effects of PPIs (dexlan-
oprazole, lansoprazole, esomeprazole, and omeprazole) on
teady-state pharmacokinetics and pharmacodynamics of
lopidogrel in healthy volunteers, as previously described in
etail (12). In the present study, we analyzed steady-state
lopidogrel pharmacokinetics and pharmacodynamics in
ealthy subjects before and after clopidogrel 75 mg/day for
days (because repeated daily doses of clopidogrel 75 mg
chieve steady-state inhibition of ADP-induced platelet
ggregation between days 3 and 7 [16,17]) in the absence of
ny PPIs. This study was conducted according to the World
edical Association Declaration of Helsinki, the Interna-
ional Conference on Harmonization Harmonized Tripar-
ite Guideline for Good Clinical Practice, and local
egulations.
nrollment criteria. Key enrollment criteria are summa-
ized in Online Table 1. In brief, healthy subjects, homozy-
ous for CYP2C19 extensive metabolizer genotype (i.e.,
Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering com-
mittees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention),
WebMD (CME steering committees); and is Senior Associate Editor, Journal of
Invasive Cardiology. Dr. Bhatt has also received research grants from Amarin,
AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, and
The Medicines Company; and he has performed unfunded research with FlowCo,
PLx Pharma, and Takeda. Drs Lee, Mulford, Wu, and Nudurupati are employees of
Takeda Global Research & Development Center, Inc. All other authors have reported
that they have no relationships relevant to the contents of this paper to disclose.t
Manuscript received August 19, 2012; revised manuscript received October 26,
2012, accepted November 27, 2012.on-carriers of CYP2C19 *2, *3,
4, *5, *6, *7, *8, *9, *10, or *17),
ged 18 to 55 years, with a body
ass index (BMI) between 18
nd 30 kg/m2, and free of nicotine
for 6 weeks, prescription drugs for 4
weeks, over-the-counter drugs
(OTC) for 2 weeks, and caffeine and
alcohol for 72 h were enrolled. All
subjects found to be CYP2C19 poor,
intermediate, or ultra-rapid metabo-
lizer genotypes were deemed screen
failures and were excluded.
Treatment period. Enrolled
subjects (cohorts of 40 subjects at
a time) were confined in a clinical
research unit for 10 consecutive
days and nights during periods 1
and 2. Subjects fasted 8 h be-
fore clopidogrel dosing. Wit-
nessed dosing of clopidogrel
commenced at 0800 h on days
1 through 9 of both periods.
Diet, fluid, and activity control.
During the confinement period,
subjects received standardized
meals and snacks and refrained
from strenuous exercise. All sub-
jects could consume water ad li-
bitum except for 1 h pre- and
post-drug administration (the
Online Appendix for details).
Genotype analysis. Genotyping
of CYP2C19 alleles (*2, *3, *4, *5,
*6, *7, *8, *9, *10, and *17 [C-
806T]) was performed as previously described (12). En-
rolled subjects were also genotyped with respect to the
following single nucleotide polymorphisms: CYP3A5 *3 and
*6, ABCB1 C3435T, and PON1 rs622 (A/G), as previously
described (5,12) (Online Appendix).
Clopidogrel pharmacokinetics. Clopidogrel active metab-
olite (clopidogrelAM) concentration in samples collected on
day 9 pre-dose and at specified times through 24 h post-
dose were determined as previously described (12) (see
Online Appendix) and used to determine the peak plasma
concentration (Cmax) and the area under the plasma
oncentration-time curve from time 0 to the time of last
uantifiable concentration (AUCt).
lopidogrel pharmacodynamics. Platelet function was
easured pre-dose on days –1, 7, 8, and 9, and at 24 h after
he day 9 dose. The pharmacodynamic effects of clopidogrel
ere evaluated by 3 platelet function tests: the vasodilator-
timulated phosphoprotein (VASP) P2Y12 assay (BioCytex,
arseille, France), ADP-stimulated light transmission ag-
regation (LTA), and platelet aggregation as reported by
Abbreviations
and Acronyms
ADP  adenosine
phosphate
AUCt  area under the
time-concentration curve
BMI  body mass index
ClopidogrelAM 
clopidogrel active
metabolite
Cmax  peak plasma
concentration
CVs  coefficients of
variation
EM/EM  homozygous
CYP2C19 extensive
metabolizer genotype
LTA  light transmission
aggregation
MPA  maximal platelet
aggregation
OTC drugs  over-the-
counter drugs
PON1  paraoxonase 1
PPI  proton pump inhibitor
Pre-Tx  pre-treatment
PRI  platelet reactivity
index
PRP  platelet rich plasma
PRU  P2Y12 reaction units
Rx drugs  prescription
drugs
VASP  vasodilator
stimulated phosphoproteinhe VerifyNow P2Y12 test (Accumetrics, San Diego, Cal-
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Clopidogrel Response Variability February 26, 2013:872–9ifornia), all as previously described (12) (see Online
Appendix).
Statistics. Data analyses were performed by A.L. Frelinger
III, PhD, Assistant Professor of Pediatrics, Harvard Med-
ical School using GraphPad Prism 5.0 (GraphPad Software,
San Diego, California) and SAS 9.2 (SAS Institute, Cary,
North Carolina) and independently confirmed by J. Wu,
PhD and S. Nudurupati, PhD, Takeda Global Research &
Development Center, Inc. using SAS 9.1 (SAS Institute).
Descriptive statistics were used to report demographics for
all enrolled subjects. Pre- versus post-treatment pharmaco-
dynamic endpoints were compared using paired Student
t-test. Partial correlations, 2, were calculated to estimate
the contribution of demographic, hematologic, and genetic
factors to clopidogrel pharmacokinetic and pharmacody-
namic endpoints while controlling for study design variables
(cohort, period, and treatment group). The effects of se-
lected polymorphisms on clopidogrel pharmacokinetics and
pharmacodynamics were evaluated within analysis of vari-
ance models with fixed factors for genotype, cohort, period,
and treatment group. General linear models with stepwise
selection for corrected Akaike’s information criterion and
fixed factors for cohort, period, and treatment group were
used to select demographic, hematologic, and genetic fac-
tors predictive of each of the pharmacokinetic and pharma-
codynamic endpoints. Effect size of each factor was esti-
mated using semipartial correlations, ˆ2. Log-transformed
values of clopidogrelAM AUCt, and Cmax were used for all
models.
Results
Subject characteristics and disposition. Five hundred
fifty-two subjects were screened and 160 subjects were
enrolled, as previously reported (12). All enrolled subjects
were genotyped as CYP2C19 *1/*1 extensive metabolizers
and had normal hematology, clinical chemistry, and urinal-
ysis results at enrollment. One hundred fifty-six of the 160
enrolled subjects completed the 9 days of treatment with
clopidogrel 75 mg and the accompanying pharmacokinetic
and pharmacodynamic measurements. Reasons for failure to
complete the study were adverse event (n  2), major
protocol violation (n  1), and pregnancy (n  1). Subject
demographics and baseline characteristics are shown in
Table 1.
Variation in clopidogrel pharmacokinetics and pharma-
codynamics. Following 9 days of treatment with clopi-
dogrel, interindividual exposure to clopidogrelAM varied
idely: AUCt and Cmax values varied more than threefold
from the 10th to the 90th percentile and the coefficients of
variation (CV) were large (34% and 40%, respectively)
(mean  SD: AUCt 41.3  14.0 ng-hr/ml; Cmax 39.6 
5.9 ng/ml) (Figs 1A and 1B, Online Table 2). As expected,
ean values for clopidogrel pharmacodynamic markers were
educed following 9 days of clopidogrel treatment (Figs. 1C
o 1F, Online Table 2). However, as was observed with tlopidogrel pharmacokinetics, clopidogrel pharmacodynam-
cs after 9 days of treatment with clopidogrel varied widely
CVs 37%, 53%, 37%, and 32% for VASP platelet reactivity
ndex [PRI], VerifyNow P2Y12 reaction units [PRU],
aximal platelet aggregation [MPA] with 5-M ADP, and
PA with 20-M ADP, respectively (Figs. 1C to 1F,
nline Table 2). This variation was not accounted for by
ay-to-day subject and/or assay variation, which was small
s judged by intraclass correlation coefficients of 80%
Online Table 3, Online Fig. 1).
Using the cutpoints suggested by an international con-
ensus group (2), high on-treatment platelet reactivity was
resent in 62 of 156 (40%) subjects by VASP PRI 50, 15
f 156 (10%) subjects by MPA with 5-M ADP 46, and
8 of 156 (5%) subjects by VerifyNow P2Y12 PRU 235
(Fig. 2). A total of 45% of healthy subjects had high
on-treatment platelet reactivity by at least 1 criterion.
Influence of demographic, hematologic, genetic, and
study design factors on clopidogrel pharmacokinetics.
Table 2 summarizes the influence of factors related to
subject demographics (age, sex, weight), hematology (plate-
let count, hematocrit), and genetics (polymorphisms of
CYP3A5, ABCB1, and PON1), on clopidogrelAM pharma-
okinetics (Cmax and AUCt). Only age and baseline weight
were significantly associated with clopidogrelAM AUCt and
Cmax. However, correlations between clopidogrelAM AUCt
and Cmax and subject weight and age indicated that only 5%
to 6% of the variation in clopidogrelAM AUCt and Cmax was
xplained by differences in weight and age (2 range: 0.0525
Subject Demographics and Baseline Characteristics(N  156)Table 1 Subject Demographics and B seline Characteristics(N  156)
Age, yrs 33.9 7.29
Min–max 20–53
Sex, n (%)
Male 79 (50.6)
Female 77 (49.4)
Weight, kg 70.4 9.74
Height, cm 164.0 8.63
BMI, kg/m2 26.1 2.33
CYP2C19†
CYP2C19 EM/EM 156 (100)
CYP3A5 *3
*3 Noncarrier 9 (6)
*3 Heterozygote 43 (28)
*3/*3 Homozygote 104 (67)
ABCB1 C3435T
C/C 44 (28)
C/T 77 (49)
T/T 35 (22)
PON1 rs662
A/A 33 (21)
A/G 90 (58)
G/G 33 (21)
†CYP2C19 genotypes evaluated: *2, *3, *4, *5, *6, *7, *8, *9, *10, and *17 (C-806T).
BMI  body mass index; EM/EM  homozygous CYP2C19 extensive metabolizer genotype.o 0.0639) (Table 2). Neither clopidogrelAM AUCt nor
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February 26, 2013:872–9 Clopidogrel Response VariabilityCmax were significantly different in men versus women.
olymorphisms in enzymes reported to affect clopidogrel
etabolism (5,6,8,18,19) (CYP3A5 *3, ABCB1 C3435T, and
ON1 rs662,) were relatively common (Table 1), but were not
orrelated with clopidogrelAM Cmax or AUCt (Table 2,
Online Table 4).
For multivariate analysis, a general linear model with
stepwise selection was used to identify demographic, hema-
tologic, and genetic factors that independently predicted
clopidogrel pharmacokinetics. The optimal model for pre-
dicting clopidogrelAM AUCt accounted for 18% of the
variation (adjusted r2  0.1789), and included age (ˆ2 
0.0384, p  0.0082) and weight (ˆ2  0.0372, p  0.0092)
s factors (Fig. 3, Online Table 5), whereas sex, platelet
ount, hematocrit, and the indicated polymorphisms in
YP3A5, ABCB1, and PON1 were not significantly associ-
ted with clopidogrelAM AUCt. Likewise, the optimal
Figure 1 Clopidogrel Pharmacokinetics and
Pharmacodynamics in Healthy Subjects
Subjects homozygous for CYP2C19 extensive metabolizer genotype on a con-
trolled diet, and free of nicotine, alcohol, prescription and nonprescription med-
ications including proton pump inhibitors. Box (25th to 75th percentile, line 
median,   mean) and whiskers (5th to 95th percentile) plots with outliers
for (A) clopidogrel active metabolite (clopidogrelAM) area under the time-
concentration curve (AUCt); (B) clopidogrelAM peak plasma concentration
(Cmax); (C) vasodilator stimulated phosphoprotein (VASP) platelet reactivity
index (PRI); (D) VerifyNow P2Y12 reaction units (PRU); (E) maximal platelet
aggregation 5-M adenosine diphosphate; and (F) maximal platelet aggrega-
tion 20-M ADP. p Values are for paired t-test (N  156).odel for predicting clopidogrelAM Cmax accounted for16% of the variation (adjusted r2  0.1552) and included
ge (ˆ2  0.0315, p  0.0179) and weight (ˆ2  0.0328,
 0.0157) (Fig. 3, Online Table 5). Thus, for both
lopidogrelAM AUCt and Cmax, 82% of the variation
remained unexplained.
Influence of demographic, hematologic, and genetic factors
on clopidogrel pharmacodynamics. Table 3 summarizes
the results of analysis of the influence of clopidogrelAM
AUCt and Cmax and factors related to subject demographics,
hematology, genetics, and baseline (pre-treatment) VASP
PRI on the on-treatment (day 9) VASP PRI. As expected,
clopidogrelAM AUCt and Cmax were predictive of VASP
PRI (r2  0.3820 and 0.2329, respectively; p  0.0001
ach) (Table 3). Like clopidogrelAM pharmacokinetic end-
points, VASP PRI did not differ significantly when analyzed
according to polymorphisms in CYP3A5, ABCB1, and
PON1 (Table 3, Online Table 6).
Figure 2 Overlap of High On-Treatment Platelet Reactivity
As determined by 3 assays in healthy, homozygous CYP2C19 extensive
metabolizer genotype subjects, free of nicotine, alcohol, prescription, and over-
the-counter medication, with witnessed clopidogrel 75 mg/day treatment for 9
days. MPA  maximum platelet aggregation; other abbreviations as in Figure 1.
Effects of Demographic, Hematologic,and Genetic Factors on ClopidogrelAMPharmacokinetics (AUCt and Cmax).
Table 2
Effects of Demographic, Hematologic,
and Genetic Factors on ClopidogrelAM
Pharmacokinetics (AUCt and Cmax).
Predictors
ClopidogrelAM AUCt ClopidogrelAM Cmax
2* p Value† 2 p Value
Age (yrs) 0.0639 0.0019 0.0525 0.0051
Weight (kg) 0.0625 0.0022 0.0540 0.0045
Platelet count 0.0205 0.0827 0.0040 0.4432
Hematocrit (%) 0.0001 0.9050 0.0008 0.7316
Sex (M  1, F  2) 0.0001 0.9013 0.0020 0.5916
CYP3A5 *3 0.0249 0.1613 0.0156 0.3197
ABCB1 C3435T 0.0109 0.4533 0.0083 0.5484
PON1 rs662 0.0118 0.4217 0.0077 0.5723
*Partial correlation (proportion of variation accounted for by the effect being tested). †p Values are
from analysis of variance models using log-transformed values of clopidogrel active metabolite
(clopidogrelAM) area under the time-concentration curve (AUCt) and peak plasma concentration
(Cmax) with factors for cohort, period, and treatment group.
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Clopidogrel Response Variability February 26, 2013:872–9The optimal multivariable model for predicting VASP
PRI (adjusted r2  0.4755 for model) (Fig. 3) included
clopidogrelAM AUCt (ˆ
2 0.3579, p 0.0001), with very small
contributions from platelet count (ˆ2 0.0195, p 0.0179), and
pre-treatment VASP PRI (ˆ2  0.0187, p  0.0205).
Evaluation of independent variables that may contribute
o clopidogrel’s effect on platelet function as measured by
erifyNow P2Y12 PRU, VerifyNow percent inhibition, and
y MPA with 5- and 20-M ADP is shown in Table 3.
lopidogrelAM AUCt and Cmax, VASP PRI, hematocrit,
and sex were each significantly associated with VerifyNow PRU,
MPA with 5-M ADP, and MPA with 20-M ADP
(Table 3). Subject age was significantly associated with
VerifyNow PRU (Table 3). A modest (r2  0.2603), but
highly significant (p  0.0001) association, was found
etween pre-treatment VerifyNow PRU and on-treatment
erifyNow PRU. Pre-treatment MPA to 5-M ADP was
nly weakly associated with on-treatment MPA to 5-M
Figure 3 Diagrammatic Representation of Factors Contributing
in Clopidogrel Pharmacokinetics and Pharmacodynam
Green arrows indicate pathway activated by adenosine diphosphate (ADP) binding
metabolite; LTA  light transmission aggregation; OTC drugs  over-the-counter d
drugs; other abbreviations as in Figures 1 and 2.ADP (Table 3).VerifyNow PRU, MPA with 5-M ADP, and MPA with
20-M ADP were not correlated with polymorphisms in
YP3A5, ABCB1, and PON1 (Table 3, Online Table 7).
The optimal multivariable models for predicting VerifyNow
RU and VerifyNow percent inhibition included factors for
lopidogrelAM pharmacokinetics, VASP PRI, hematocrit,
and for VerifyNow PRU, pre-treatment VerifyNow PRU.
Together these factors explained 65% and 57% of the
variation in VerifyNow PRU and VerifyNow percent inhi-
bition, respectively (r2  0.6500 and 0.5738, respectively)
Fig. 3, Online Table 8). Cmax, although highly correlated
with clopidogrelAM AUCt, was a slightly better predictor of
VerifyNow percent inhibition than clopidogrelAM AUCt,
nd was therefore included in the final model for prediction
f VerifyNow percent inhibition. The optimal multivariable
odel for predicting MPA to 5-M ADP included factors
or clopidogrelAM AUCt, baseline hematocrit, and pre-
treatment MPA with 5-M ADP and accounted for 35% of
ariability
12. AUC  area under the time-concentration curve; CAM  clopidogrel active
re-Tx, pre-treatment; PRP  platelet rich plasma; Rx drugs  prescriptionto V
ics
to P2Y
rugs; Pvariation in MPA with 5-M ADP (r2  0.3519) (Fig. 3,
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February 26, 2013:872–9 Clopidogrel Response VariabilityOnline Table 8). Likewise, the optimal model to predict
MPA with 20-M ADP included factors for clopidogrelAM
AUCt, VASP PRI, sex, and pre-treatment MPA with
20-M ADP and accounted for 44% of variation in MPA
with 20-M ADP (r2  0.4357) (Fig. 3, Online Table 8).
iscussion
he main findings of this study are the following. 1) Despite the
igorous elimination of variation in CYP2C19 polymor-
hisms, compliance, diet, nicotine, and prescription and
onprescription medications (including PPIs and statins),
lopidogrel pharmacokinetics and pharmacodynamics still
aried widely. 2) Differences within the study population
ith respect to age, weight, sex, platelet count, hematocrit,
nd polymorphisms in CYP3A5, ABCB1, or PON1 ac-
ounted for only 18% of the variability in clopidogrelAM
AUCt, and Cmax, leaving 82% of the variability unex-
plained. 3) These factors, together with each subject’s
clopidogrelAM AUCt and Cmax, accounted for only 48%
f the variability in ADP-induced signaling through P2Y12
as measured by VASP phosphorylation, leaving 52% of
the variability unexplained. 4) Differences in the preceding
factors, clopidogrelAM AUCt, and Cmax, and P2Y12 signal-
ng together accounted for 35% to 65% of the variability in
latelet aggregation in platelet-rich plasma or whole blood,
eaving 35% to 65% of the variability unexplained. 5) Pre-
reatment variability in platelet reactivity was a significant,
lbeit minor, contributor to on-treatment platelet reactivity.
) Variation in clopidogrel pharmacokinetics and pharma-
odynamic parameters were not associated with polymor-
hisms in CYP3A5, ABCB1, or PON1. Because patients
Effects of Individual Demographic, Hematologic, and Genetic FactoTable 3 Effects of Individual Demographic, Hematologic, and G
Predictors
VASP PRI VerifyNow PRU
2* p Value† 2 p Va
ClopidogrelAM AUCt 0.3820 <0.0001 0.2966 <0.0
ClopidogrelAM Cmax 0.2329 <0.0001 0.2374 <0.0
Pre-treatment VASP PRI 0.0070 0.3099
Pre-treatment VerifyNow PRU 0.2603 <0.0
Pre-treatment VerifyNow % Inh.
Pre-treatment MPA 5-M ADP
Pre-treatment MPA 20-M ADP
VASP PRI 0.2628 <0.0
Hematocrit (%) 0.0010 0.7201 0.2699 <0.0
Sex (M  1, F  2) 0.0013 0.6581 0.2241 <0.0
Age (yrs) 0.0098 0.2300 0.0450 0.0
Weight (kg) 0.0172 0.1114 0.0131 0.1
Platelet count 0.0016 0.6309 0.0021 0.5
CYP3A5 *3 0.0266 0.1402 0.0075 0.5
ABCB1 C3435T 0.0092 0.5075 0.0021 0.8
PON1 rs662 0.0027 0.8190 0.0024 0.8
*Partial correlation (proportion of variation accounted for by the effect being tested). †p Values are f
or cohort, period, and treatment group.
ADP  adenosine diphosphate; MPA  maximal platelet aggregation; PRI  platelet reactivity
as in Table 2.ith reduced platelet inhibition during clopidogrel treat-ent have an increased risk for major adverse cardiovascular
vents (2), the present findings, summarized diagrammati-
ally in Figure 3, are important. For example, the presently
escribed wide variability in clopidogrel pharmacokinetics
nd pharmacodynamics independent of known factors (in-
luding single nucleotide polymorphisms, noncompliance,
iet, smoking, and co-medications) provides a pharmaco-
ogical explanation for the relative lack of effect of clopi-
ogrel in nonsmokers (10) and strongly suggests that
herapeutic strategies based on the CYP2C19*2 polymor-
hism (20) will not eliminate the increased risk for major
dverse cardiovascular events in patients with high on-
reatment platelet reactivity.
The Food and Drug Administration has issued a “black
ox warning” for clopidogrel (17,21) that alternative treat-
ent should be considered in patients identified as
YP2C19 poor metabolizers based on the CYP2C19 poly-
orphism. However, our study demonstrates that even in
ealthy homozygous CYP2C19 extensive metabolizer sub-
ects free of nicotine, alcohol, prescription, and OTC
edications, and with witnessed compliance to study med-
cation, there is a high frequency of poor response to
lopidogrel (45% had high on-treatment platelet reactivity
y at least 1 criterion). In the present study, rigorous
easures were taken to eliminate or control potential
ontributors to clopidogrel variability, thereby allowing us to
etermine if the observed variation might be explained by
easurable demographic factors. However, clopidogrelAM
pharmacokinetics varied widely despite these controls and
adjustments for demographics (Fig. 1, Online Table 2),
leaving the source of 82% of the variability unknown.
Clopidogrel Pharmacodynamicsc Factors on Clopidogrel Pharmacodynamics
VerifyNow % Inhibition MPA 5-m ADP MPA 20-m ADP
2 p Value 2 p Value 2 p Value
0.3848 <0.0001 0.2208 <0.0001 0.2895 <0.0001
0.3320 <0.0001 0.1948 <0.0001 0.2370 <0.0001
0.0250 0.0540
0.0269 0.0458
0.0167 0.1165
0.3771 <0.0001 0.1447 <0.0001 0.1976 <0.0001
0.0881 0.0002 0.0785 0.0005 0.0547 0.0041
0.0813 0.0004 0.0656 0.0016 0.0781 0.0006
0.0413 0.0129 0.0229 0.0656 0.0231 0.0644
0.0001 0.8867 0.0001 0.9229 0.0027 0.5256
0.0002 0.8622 0.0000 0.9904 0.0005 0.7916
0.0104 0.4656 0.0072 0.5921 0.0078 0.5656
0.0028 0.8174 0.0034 0.7806 0.0035 0.7745
0.0005 0.9620 0.0001 0.9954 0.0061 0.6400
alysis of variancemodels using log-transformed values of clopidogrelAM AUCt and Cmax with factors
RU  P2Y12 reaction units; VASP  vasodilator stimulated phosphoprotein. Other abbreviationsrs oneneti
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polymorphisms) and nongenetic sources of variation in
clopidogrel absorption and metabolism.
Multiple studies confirmed a role for CYP2C19*2 in both
he laboratory and clinical response to clopidogrel (2). A
enome-wide association study found that variation in
latelet function following clopidogrel administration was
ighly heritable (22), but the CYP2C19*2 polymorphism
ccounted for (only) 12% of the variation in platelet
ggregation (22). The high heritability estimate suggests
hat additional genetic variants may contribute to clopi-
ogrel response variability. Bouman et al. (5) proposed that
ON1 plays a major role in clopidogrel metabolism and that
common polymorphism in PON1, rs662, affects the rate of
lopidogrelAM formation. However, other investigators
ound no significant effect of the PON1 rs662 polymor-
hism on clopidogrel pharmacokinetics or pharmacody-
amics (23–26). In the present study, the PON1 rs662
olymorphism was not significantly associated with clopi-
ogrel pharmacokinetic or pharmacodynamic endpoints
Tables 2 and 3, Online Tables 4, 6, and 7). This finding
dds to and complements previous findings (23–26), be-
ause in the present study, possible confounding factors
subject health, co-medications, smoking, diet, and
YP2C19 genotype) were eliminated or controlled by study
esign. Likewise, and in contrast to some reports
6,8,18,19), in the present, rigorously controlled study, no
ssociations were observed between polymorphisms in
BCB1 (C3435T) or CYP3A5 (*3) and clopidogrel pharma-
cokinetic or pharmacodynamic endpoints (Tables 2 and 3,
Online Tables 4, 6, and 7).
Considering the small number of biochemical steps
between ADP binding to P2Y12 and changes in VASP
phosphorylation (27), a surprising result of the present study
is that the measured clopidogrel pharmacokinetics explain
only 48% of the variability in clopidogrel pharmacody-
namics as measured by the VASP assay. Potential explana-
tions for this phenomenon include quantitative or qualita-
tive differences in signaling molecules between P2Y12 and
ASP, such as Gi, adenylyl cyclase, or protein kinase A.
ClopidogrelAM AUCt and Cmax values also had an
nexpectedly small influence on variation in platelet aggre-
ation measured by LTA or VerifyNow, accounting for
40% of the variation in platelet aggregation assays (Table 3).
his may be explained in part by the fact that platelet
ggregation is well downstream from the platelet ADP
eceptor, P2Y12 (the molecular target for clopidogrel’s active
metabolite) and is dependent on glycoprotein IIb-IIIa
(integrin IIb3) receptor density, fibrinogen, platelet con-
entration, and cell–cell contact. VASP phosphorylation is
istal to signaling through P2Y12, but upstream from
lycoprotein IIb-IIIa activation and platelet aggregation
Fig. 3). Because signaling through P2Y12, as measured by
ASP phosphorylation, varied from that predicted on the
asis of clopidogrelAM pharmacokinetics, we evaluated the
bility of VASP PRI to independently predict plateletggregation measured by 5- and 20-M ADP-induced
LTA and the VerifyNow P2Y12 assay. VASP PRI ac-
counted for 4% and 14% of the variation in VerifyNow
PRU and VerifyNow percent inhibition, respectively, and
2% of the variation in MPA to 20-M ADP (Fig. 3,
Online Table 8) independent of pharmacokinetics and other
predictors. Thus, variation in signaling between P2Y12 and
VASP phosphorylation accounts for a small portion of the
variation in these platelet aggregation endpoints; a portion
of the remaining variation may be due to variation in
signaling distal to VASP.
Approximately 35%, 44%, and 65% of the variation in 5-
and 20-M ADP-induced LTA, and the VerifyNow
P2Y12 assay, respectively, could be explained by identified
factors in the present study (Fig. 3). In an analysis of the
POPular (Do Platelet Function Assays Predict Clinical
Outcomes in Clopidogrel-Pretreated Patients Undergoing
Elective PCI) study, Bouman et al. (28) demonstrated that,
in addition to the CYP2C19*2 genotype, high on-treatment
platelet reactivity could be independently predicted by
clinical factors (demographics, disease, drug use, etc.).
When these clinical factors were combined with CYP2C19*2
polymorphism as predictors, 13.0%, 15.2%, and 20.6% of the
variability in 5- and 20-M ADP-induced LTA, and the
VerifyNow P2Y12 assay, respectively, could be explained
(28). However, the level of clopidogrelAM, arguably the
most critical determinant of the response to clopidogrel, was
not measured in POPular. Thus, in POPular (unlike the
present study), it was not possible to estimate the total
proportion of clopidogrel response variation that could be
explained by all known factors.
We, and others, have previously reported that pre-
treatment platelet reactivity is a predictor of platelet reac-
tivity during clopidogrel treatment (13–15). Here, we dem-
onstrate that when known contributors to variation in
clopidogrel’s pharmacodynamic response are removed, in-
trinsic pre-treatment platelet reactivity remains a significant,
albeit modest (Table 3), predictor of on-treatment variation,
accounting for 2% of variation in platelet reactivity as
measured by 3 independent assays. Finally, the proportion
of variance due to error in these measures may be nontrivial,
although the very high intraclass correlations (0.8) (On-
line Table 3) suggests intraindividual variability (which
includes assay error) is low.
Study limitations. First, this study was conducted in con-
fined healthy volunteers, not patients, but this enabled us to
rigorously control for co-medications, diet, smoking, clopi-
dogrel compliance, etc., and to exclude known disease as a
contributor to variability. Furthermore, the presently de-
scribed high degree of variability in clopidogrel response in
healthy volunteers would likely only be higher in patients
with activated platelets due to acute coronary syndromes or
additional co-morbidities such as diabetes mellitus. Second,
for uniformity, this study included only homozygous
CYP2C19 extensive metabolizers; consequently, our conclu-
sions are limited to this population.
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February 26, 2013:872–9 Clopidogrel Response VariabilityConclusions
Steady-state clopidogrel pharmacokinetics and pharmaco-
dynamics vary widely despite exclusion or control of known
factors: polymorphisms (CYP2C19, CYP3A5, ABCB1,
PON1), noncompliance, diet, smoking, co-medications (in-
cluding PPIs and statins), alcohol, demographic factors, and
pre-treatment platelet hyperreactivity. Identifiable factors
account for only 18% of the variation in clopidogrelAM
pharmacokinetics and only 35% to 65% of the variation in
on-treatment platelet reactivity measured by VASP, LTA,
and VerifyNow. Sources of the remaining variations are
unclear, but they may be future therapeutic targets, given
that patients with high on-treatment platelet reactivity are
at increased risk of major adverse cardiovascular events.
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APPENDIX
For an expanded Methods section and the supplemental Figure and Tables,
please see the online version of this article.
